Abeona Therapeutics (NASDAQ:ABEO) Issues Earnings Results

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03, FiscalAI reports. The firm had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $4.57 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN launch momentum is building, with Abeona treating 5 commercial patients to date, activating 6 qualified treatment centers, and reporting $8.7 million in Q1 2026 net product revenue.
• Management said payer coverage is broadening, with published policies now covering 95% of commercially insured lives and no final payer denials or patient attrition reported so far.
• The company highlighted a deepening patient pipeline, including more than 100 identified patients across centers and the community, plus 45 active referral physicians and several biopsies scheduled this quarter.
• Abeona announced an in-licensed PSMA CAR-T asset for advanced prostate cancer, paid a $7 million upfront fee, and expects first-in-human studies to begin in the second half of 2027 after a June 2026 pre-IND meeting.
• Management said the balance sheet remains strong with $168.3 million in cash and short-term investments, and reiterated expectations for near-term profitability depending on biopsy and treatment cadence.

Abeona Therapeutics Stock Down 1.9%

Shares of ABEO traded down $0.11 during midday trading on Thursday, reaching $5.60. 1,101,848 shares of the company were exchanged, compared to its average volume of 1,208,791. The stock has a 50-day moving average price of $5.07 and a 200-day moving average price of $5.04. The company has a market cap of $318.60 million, a price-to-earnings ratio of 5.45 and a beta of 1.35. Abeona Therapeutics has a 1-year low of $4.00 and a 1-year high of $7.54. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, insider Madhav Vasanthavada sold 5,548 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $5.96, for a total transaction of $33,066.08. Following the transaction, the insider owned 313,071 shares in the company, valued at $1,865,903.16. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new position in shares of Abeona Therapeutics in the second quarter worth about $27,000. Russell Investments Group Ltd. acquired a new position in shares of Abeona Therapeutics in the third quarter worth about $37,000. Truvestments Capital LLC lifted its stake in shares of Abeona Therapeutics by 191.4% in the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 6,770 shares in the last quarter. Man Group plc acquired a new position in shares of Abeona Therapeutics in the second quarter worth about $67,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Abeona Therapeutics in the third quarter worth about $64,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Wall Street Analyst Weigh In

ABEO has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, March 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Finally, Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a research report on Tuesday, March 17th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.